 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Prevail Therapeutics Inc. (NASDAQ:PRVL) has been assigned a consensus rating of
  Hold from the eleven research firms that are presently covering the stock, Marketbeat
  Ratings reports. One analyst has rated the stock with a sell recommendation, seven
  have assigned a hold recommendation ...


Brokerages Set Prevail Therapeutics Inc. (NASDAQ:PRVL) Price Target at $24.00

---
- Eli Lilly and Company shares rise (LLY +2.4%) on the back of the drugmaker's completion
  of its acquisition of Prevail Therapeutics (PRVL) enabling the creation of a gene
  therapy program...


Eli Lilly shares up as it completes Prevail Therapeutics deal

---
- Gamida Cell (NASDAQ:GMDA) and Prevail Therapeutics (NASDAQ:PRVL) are both small-cap
  medical companies, but which is the superior investment? We will compare the two
  companies based on the strength of their dividends, institutional ownership, valuation,
  analyst recommendations, risk, profitability ...


Reviewing Gamida Cell (NASDAQ:GMDA) and Prevail Therapeutics (NASDAQ:PRVL)

---
- Lilly Completes Acquisition of Prevail Therapeutics Lilly Completes Acquisition
  of Prevail Therapeutics PR Newswire INDIANAPOLIS, Jan. 22, 2021 INDIANAPOLIS, Jan.
  22, 2021 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY) today announced the successful
  completion of its acquisition of Prevail ...


Lilly Completes Acquisition of Prevail Therapeutics

---
- Prevail getting bought by Eli Lilly for $22.50 plus a potential $4.00 in CVR payments.
  The payment terms are straightforward and the timeline is long here, which improves
  the chances of the...


Prevail Therapeutics Shareholders Are Getting A Big Contingent Value Right

---
- Prevail Therapeutics (NASDAQ:PRVL) was downgraded by Zacks Investment Research from
  a hold rating to a strong sell rating in a research report issued to clients and
  investors on Tuesday, Zacks.com reports. According to Zacks, Prevail Therapeutics
  Inc. is a gene therapy company. It focuses on ...


Prevail Therapeutics (NASDAQ:PRVL) Stock Rating Lowered by Zacks Investment Research

---
- Prevail Therapeutics Inc. (NASDAQ:PRVL) was the recipient of a significant decrease
  in short interest in the month of December. As of December 31st, there was short
  interest totalling 1,100,000 shares, a decrease of 47.6% from the December 15th
  total of 2,100,000 shares. Based on an average daily ...


Prevail Therapeutics Inc. (NASDAQ:PRVL) Short Interest Update

---
- Prevail Therapeutics Inc. (NASDAQ:PRVL) has been assigned an average recommendation
  of Hold from the thirteen research firms that are currently covering the stock,
  MarketBeat.com reports. One equities research analyst has rated the stock with a
  sell recommendation, nine have given a ...


Analysts Set Prevail Therapeutics Inc. (NASDAQ:PRVL) Target Price at $24.00

---
- Charles Schwab Investment Management Inc. lessened its holdings in shares of Prevail
  Therapeutics Inc. (NASDAQ:PRVL) by 4.9% in the third quarter, according to its most
  recent filing with the SEC. The firm owned 33,282 shares of the companys stock after
  selling 1,724 shares during the quarter...


Prevail Therapeutics Inc. (NASDAQ:PRVL) Shares Sold by Charles Schwab Investment Management Inc.

---
- 'SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson
  Fistel, LLP has launched an investigation into whether the board members of Prevail
  Therapeutics Inc. ("Prevail" or the "Company") (NASDAQ: PRVL) breached their fiduciary
  duties in connection with the proposed sale of ...'


(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

Watchers	435
52-Wk Low	$9.02
52-Wk High	$23.35

Market Cap	$787.7M
Volume (M)	2.62M
52-Wk High	$23.35
52-Wk Low	$9.02

PRVL Prevail Therapeutics

About

Feed

News

Fundamentals